本文選題：念珠菌食管炎 + 布拉氏酵母菌��； 參考：《山西醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:通過(guò)藥物臨床試驗(yàn)對(duì)比布拉氏酵母菌與制霉菌素治療念珠菌食管炎的臨床療效,探討布拉氏酵母菌治療念珠菌食管炎的臨床療效及安全性。方法:采用單中心、前瞻性、開(kāi)放標(biāo)簽、隨機(jī)對(duì)照的非劣性試驗(yàn)設(shè)計(jì)。將符合納入標(biāo)準(zhǔn)和剔除標(biāo)準(zhǔn)念珠菌食管炎患者根據(jù)隨機(jī)數(shù)字表法分為布拉氏酵母菌組(45例)和制霉菌素組(44例)。兩組患者分別給予口服布拉氏酵母菌散和制霉菌素片治療。療程結(jié)束后復(fù)查胃鏡以評(píng)價(jià)其療效。采用非劣性檢驗(yàn)比較兩組治愈率差異。結(jié)果:布拉氏酵母菌組和制霉菌素組治愈率分別為68.9%和63.6%。采用非劣性檢驗(yàn)計(jì)算得出統(tǒng)計(jì)量u=3.027,P=0.0013,拒絕無(wú)效假設(shè),可認(rèn)為布拉氏酵母菌治愈率非劣于制霉菌素�？ǚ綑z驗(yàn)比較兩組有效率(分別為91.1%和93.2%)差異無(wú)統(tǒng)計(jì)學(xué)意義(P=1.000),而不良反應(yīng)發(fā)生率分別為2.2%和22.7%,顯示布拉氏酵母菌組明顯低于制霉菌素組,差異有統(tǒng)計(jì)學(xué)意義(P=0.003)。結(jié)論:布拉氏酵母菌治療念珠菌食管炎治愈率非劣于制霉菌素,且不良反應(yīng)發(fā)生率低,可作為治療念珠菌食管炎的治療方案之一。
[Abstract]:Objective: To compare the clinical efficacy of yeast and nystatin in the treatment of Candida esophagitis, and to explore the clinical efficacy and safety of Candida esophagitis by Saccharomyces cerevisiae. Methods: a single center, prospective, open label, and randomised non inferiority test will be adopted. The patients with Candida esophagitis were divided into the yeast group (45 cases) and the nystatin group (44 cases) according to the random digital table method. The two groups were given oral yeast powder and Nystatin Tablets respectively. After the treatment, the gastroscopy was reviewed to evaluate the curative effect. The difference of cure rate between the two groups was compared by non inferiority test. Results: bra The cure rates of yeast and nystatin groups were 68.9% and 63.6%., respectively, using non inferiority test to calculate u=3.027, P=0.0013, and rejection hypothesis. It was considered that the cure rate of yeast was not inferior to that of nystatin. The efficiency of two groups (91.1% and 93.2% respectively) was not statistically significant (P=1.000), but no statistical significance (91.1% and 93.2% respectively). The rate of good reaction was 2.2% and 22.7% respectively, which showed that the yeast group was significantly lower than the nystatin group. The difference was statistically significant (P=0.003). Conclusion: the cure rate of Candida albicans is not inferior to that of nystatin, and the incidence of adverse reaction is low, which can be used as one of the treatment schemes for Candida esophagitis.

【學(xué)位授予單位】：山西醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R571

【參考文獻(xiàn)】

相關(guān)期刊論文 前2條

1 牛海靜;蘇秉忠;;消化道真菌及其相關(guān)疾病研究進(jìn)展[J];中國(guó)真菌學(xué)雜志;2015年06期

2 劉玉秀,姚晨,陳峰,陳啟光,蘇炳華;非劣性/等效性試驗(yàn)的樣本含量估計(jì)及統(tǒng)計(jì)推斷[J];中國(guó)新藥雜志;2003年05期

，

本文編號(hào)：1897090